HER2 positive breast cancer

被引：0
|
作者：
Gianni, Luca
Bianchini, Giampaolo
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-ED11-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ED11-2
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Immune Effects of Transtuzumab in HER2 Positive Breast Cancer
    Zgura, Anca
    Gales, Laurentia
    Haineala, Bogdan
    Bratila, Elvira
    Mehedintu, Claudia
    Barac, Ramona Ileana
    Berceanu, Costin
    Andreescu, Cristina Veronica
    Brinduse, Lacramioara Aurelia
    Ionescu, Alec
    Anghel, Rodica
    REVISTA DE CHIMIE, 2019, 70 (08): : 2791 - 2794
  • [32] What therapies are on the horizon for HER2 positive breast cancer?
    Viale, Giulia
    Morganti, Stefania
    Ferraro, Emanuela
    Zagami, Paola
    Marra, Antonio
    Curigliano, Giuseppe
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (09) : 811 - 822
  • [33] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [34] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [35] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [36] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [38] Identifying efficacy of targeted HER2 antibodies in sensitization of HER2 positive breast cancer to fractionated radiation
    Song, Patrick N.
    Lu, Yun
    Napier, Tiara
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Sorace, Anna G.
    CANCER RESEARCH, 2021, 81 (04)
  • [39] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [40] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
12345